Wednesday, September 17, 2014 4:33:47 PM
HEPI has added a new director. One with significant experience in not only the financial end of the biotech market but practical biotech experience.
Someone should probably give her a call and let her know the "game is over" although my guess is ... just a hunch ... she very likely did her own investigation of HEPI before agreeing to come on board.
Another positive move for HEPI. A huge step up from John Gorman. Maybe Ms Masterson will be able to school up Dahl and Rice on the importance of strategic messaging and public/capital markets.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Nola E. Masterson
Age: 67
Director since 2014
Ms. Masterson was appointed in September 2014 to serve as a director of the Company. Since 1982, she has been the chief executive officer of Science Futures, Inc., an investment and advisory firm. Ms. Masterson is currently Managing Member and General Partner of Science Futures LLC, I and II, which are venture capital funds invested in life science funds and companies. She serves on the audit committee, nominating committee and the compensation committee for Repros Therapeutics Inc. Ms. Masterson was a biotechnology analyst on Wall Street, working with Drexel Burnham Lambert and Merrill Lynch, and is a co-founder of Sequenom, Inc., a genetic analysis company located in San Diego, California and Hamburg, Germany. Ms. Masterson is the Chair Emeritus of the Bay Bio Institute, a 501(c) 3 and part of BayBio, which promotes science education, workforce development and best practices as well as entrepreneurs in the bioeconomy. Ms. Masterson began her business career at Ames Company, a division of Bayer, and spent eight years at Millipore Corporation in sales and sales management. Ms. Masterson has 33 years of experience in the life science industry. She received her Masters in Biological Sciences from George Washington University, and continued Ph.D. work at the University of Florida. Ms. Masterson provides us with the benefit of her extensive experience as an entrepreneur and an analyst on Wall Street, as well as her 30 years of investment advisory expertise in the life sciences industry.
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
http://www.sciencefuturesinc.com/index.html
http://www.reprosrx.com/about_management.php
Amigo Mike
Recent ZIVO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
- ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM